Page last updated: 2024-09-05

lapatinib and Hyperplasia

lapatinib has been researched along with Hyperplasia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arteaga, CL; Balko, JM; Cheng, H; Cook, RS; Kuba, MG; Owens, P; Perou, CM; Pfefferle, AD; Rexer, BN; Sánchez, V; Young, CD; Zhao, JJ	1
Bonanni, B; Decensi, A; Dotti, MC; Galimberti, V; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Macis, D; Pala, O; Pruneri, G; Puntoni, M; Serrano, D; Veronesi, P; Viale, G	1

Trials

1 trial(s) available for lapatinib and Hyperplasia

Article	Year
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Female; Humans; Hyperplasia; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lapatinib; Middle Aged; Placebos; Prevalence; Quinazolines; Receptor, ErbB-2; Time Factors	2011

Article

Year

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8

Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Female; Humans; Hyperplasia; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lapatinib; Middle Aged; Placebos; Prevalence; Quinazolines; Receptor, ErbB-2; Time Factors

2011

Other Studies

1 other study(ies) available for lapatinib and Hyperplasia

Article	Year
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer research, 2013, Jul-01, Volume: 73, Issue:13 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression; Humans; Hyperplasia; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Transcriptome; Tumor Burden	2013

Article

Year

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Cancer research, 2013, Jul-01, Volume: 73, Issue:13

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression; Humans; Hyperplasia; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Transcriptome; Tumor Burden

2013